LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) VALUES AMONG HIGH CARDIOVASCULAR RISK PATIENTS IN A REAL WORLD POPULATION

被引：0
|
作者：
Punekar, Rajeshwari S.
Fox, Kathleen
Richhariya, Akshara
Gandra, Shravanthi
Cziraky, Mark
Paoli, Carly
Toth, Peter
机构：
[1] HealthCore Inc, Wilmington, DE USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2016年 / 67卷 / 13期
关键词：
D O I：
10.1016/S0735-1097(16)32035-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1271-392
引用
收藏
页码：2034 / 2034
页数：1
相关论文
共 50 条
  • [1] Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough?
    Kostapanos, Michael S.
    Katsiki, Niki
    Elisaf, Moses S.
    Mikhailidis, Dimitri P.
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (02) : 173 - 177
  • [2] INFLUENCE OF EXTREME HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) VALUES ON THE CALCULATION OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) USING FRIEDEWALD FORMULA
    Timon-Zapat, J.
    Laserna-Mendieta, E. J.
    Pineda-Tenor, D.
    Cabezas-Martinez, M. A.
    Gomez-Serranillos, M.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S345 - S345
  • [3] Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
    Whayne, Thomas F., Jr.
    CURRENT VASCULAR PHARMACOLOGY, 2017, 15 (04) : 374 - 379
  • [4] AN ANALYSIS OF THE RESIDUAL RISK OF CARDIOVASCULAR EVENTS IN PATIENTS AT LOW DENSITY LIPOPROTEIN (LDL-C) TARGET LEVELS
    Simko, R.
    Balu, S.
    Cziraky, M.
    Sarawate, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 97 - 97
  • [5] Time for new low density lipoprotein cholesterol (LDL-C) targets?
    Daskalopoulou, Stella S.
    Mikhailidis, Dimitri P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1539 - 1541
  • [6] Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among patients aged ≥ 65 years treated with rosuvastatin compared to other statins in real-world clinical practice
    Harley, Carolyn R.
    Gandhi, Sanjay K.
    Blasetto, James W.
    Heien, Herbert
    Sasane, Rahul
    Nelson, Stephanie P.
    CIRCULATION, 2007, 115 (21) : E582 - E582
  • [7] Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
    Wang, Xing
    He, Yan
    Wang, Tao
    Li, Chunming
    Ma, Zihui
    Zhang, Heng
    Ma, Handong
    Zhao, Hongxin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (04) : 307 - 315
  • [8] ADHERENCE TO STATIN TREATMENT AND ACHIEVING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) GOALS IN AN EMPLOYEE POPULATION
    Chen, C. Y.
    Burton, W. N.
    Schultz, A. B.
    Tunceli, K.
    Edington, D. W.
    VALUE IN HEALTH, 2009, 12 (03) : A143 - A144
  • [9] COMPARATIVE EFFECTIVENESS OF ROSUVASTATIN VERSUS OTHER STATINS ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) REDUCTION IN HIGH RISK PATIENTS
    Tunceli, O.
    Quinlan, S.
    Balu, S.
    Deshpande, G.
    Anzalone, D.
    Cziraky, M. J.
    Jacobson, T. A.
    VALUE IN HEALTH, 2014, 17 (03) : A104 - A105
  • [10] Zoledronic acid increases high-density lipoprotein cholesterol (HDL-C) and decreases low-density lipoprotein cholesterol (LDL-C) in multiple myeloma patients
    Gozzetti, A.
    Martini, G.
    Avanzati, A.
    Franci, B.
    Marchini, E.
    Nuti, R.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 149
12345